ProQR Therapeutics
Update in progressPRQR (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
ProQR Therapeutics N.V. is a clinical-stage biotechnology company developing novel medicines using its Axiomer RNA editing platform for genetic disorders. Its pipeline includes AX-0810 for NTCP-related cholestatic diseases, AX-2402 for Rett syndrome, AX-2911 for metabolic dysfunction-associated steatohepatitis, and AX-1412 for cardiovascular diseases. It collaborates with Eli Lilly on liver and nervous-system targets and was founded in 2012, based in Leiden, the Netherlands.
Company score
- Sentiment
- 0.28
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.17
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationNetherlands
- CEOMr. Daniel Anton de Boer
- Founded2012
- Employees186
- Websitewww.proqr.com
Identifiers
- ISINNL0010872495
- FIGIBBG006N8B830
- CUSIPN71542109
- CIK0001612940